BioSpace News Archive

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the appointment of Elie G. Hanania, Ph.D., as vice president, process development, viral vector technologies.

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, announced that the Spanish Agency of Medicines and Medical Devices has authorized the expansion to clinical sites in Spain of the Company’s multi-center, placebo-controlled, randomized, dose-finding, Phase II trial of AllocetraTM in patients with pneumonia-associated sepsis.

IN8bio, Inc. today announced presentations at three scientific conferences in November. Event: Protein & Antibody Engineering Summit (PEGS) Europe

Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed from Evotec SE in April 2021.

InMode Ltd. today announced that Moshe Mizrahy , Chief Executive Officer and Yair Malca , Chief Financial Officer will participate in the following upcoming virtual investor conferences:

Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced that Woodrow Myers, M.D., M.B.A., joins Sera as an advisor focusing on public and political affairs.

Relmada Therapeutics, Inc. today announced that it will report its financial results for the third quarter and nine months ended September 30, 2021 after the market close on Thursday, November 11, 2021

Dendreon Pharmaceuticals and Shoreline Biosciences announced an alliance to advance the future of iPSC-derived cellular therapies.

Nov. 4, 2021 12:00 UTC GenBody’s direct anterior nasal swab COVID-19 antigen test becomes the company’s second test to receive FDA Emergency Use Authorization

Ambrx Biopharma Inc. today announced the first patient has been dosed in its global ACE-Breast-03 Phase 2 clinical study of ARX788 in patients with HER2-positive metastatic breast cancer.